by | Oct 13, 2023 | Dodson, Karen, Ellebedy, Ali, Feldman, Mario, Hultgren, Scott, Pinkner, Jerome, Tamadonfar, Kevin, Timm, Morgan
— Technology Description
Researchers in Scott Hultgren’s laboratory at Washington University have created two prospective vaccine treatments designed to prevent the colonization of prominent uropathogens. These vaccines have potential for treating urinary tract infections (UTIs) with specific m…
by | Jul 16, 2020 | Feldman, Mario
— Technology Description
Researchers in Prof. Mario Feldman’s laboratory have developed a patented, versatile, cost-effective platform for creating new multivalent vaccines for a variety of Gram-negative and Gram-positive bacteria. This technology, glycoengineered outer membrane vesicles (geOM…
by | Jul 15, 2020 | Rothlauf, Paul, Whelan, Sean
— Background: Recombinant vesicular stomatitis virus (VSV) has successfully been used to create a vaccine for Ebola virus that is currently on the market. Previously, Professor Sean Whelan and colleagues have exploited the VSV platform to create similar vectors for both SARS and MERS.
Technology: The…
by | Jun 4, 2020 | Curiel, David, Diamond, Michael, Dmitriev, Igor, Hassan, Ahmed
— Technology Description
Researchers at Washington University in St. Louis have developed a chimpanzee adenovirus-based vaccine for COVID-19. COVID-19, the clinical syndrome caused by SARS-CoV-2 infection, has had extensive morbidity and mortality impacts and destabilized society. There is an urg…
by | Dec 18, 2019 | Diamond, Michael, Fernandez, Estefania, Fremont, Daved, Nelson, Christopher, Platt, Derek, Zhao, Haiyan
— To generate a panel of antibodies against ZIKV, we serially infected Irf3/ mice 30 days apart with ZIKV MR-766 (Uganda, 1947) and ZIKV H/PF/2013 (French Polynesia, 2013). Irf3/ mice were used instead of wild-type (WT) mice, because ZIKV strains are deficient in evading type I interferon-mediated imm…